Skip to content

Study of the Prevalence of Endometriosis and Adenomyosis

Study of the Prevalence of Endometriosis and Adenomyosis in Women of Childbearing Age Consulting for Non-medical Oocyte Self-preservation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06211569
Acronym
PrevADEOSE
Enrollment
400
Registered
2024-01-18
Start date
2024-04-04
Completion date
2028-01-01
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective Fertility Preservation

Keywords

Endometriosis, Adenomyosis, Prevalence, Elective fertility preservation, Transvaginal pelvic ultrasound

Brief summary

Our study aims to assess the prevalence of adenomyosis and endometriosis in patients consulting for elective fertility preservation through the diagnosis of these pathologies by transvaginal pelvic ultrasound. Imaging data will be compared with clinical data (patient characteristics, clinical symptoms) as well as the assessment of anxiety, depression, and quality of life collected from the women.

Detailed description

Adenomyosis and endometriosis are two heterogeneous benign gynecological pathologies, in terms of the presence of diverse phenotypes and their symptomatic presentation: While some women are entirely asymptomatic, others experience pelvic pain, infertility, or abnormal uterine bleeding. Assessing the prevalence of these two pathologies is challenging: On the one hand, a significant number of women are asymptomatic and not considered in the calculation; on the other hand, endometriosis and adenomyosis are often underdiagnosed, leading to delayed diagnosis. Endometriosis and adenomyosis are frequently associated. Improving knowledge about the epidemiology of endometriosis and adenomyosis is crucial as both are major causes of clinical symptoms that adversely affect the quality of life in numerous women. This is a significant issue for women's health due to the associated suffering, numerous surgical interventions, healthcare expenses, and the suggested link with pathologies that may affect other organs. Understanding the disease could lead to improved treatment and the development of preventive strategies. Therefore, it is urgent to determine the frequency of endometriosis and adenomyosis, as well as the correlation between women's characteristics, especially their clinical symptoms, and different phenotypes. In order to assess the prevalence of adenomyosis and endometriosis in a population of women of reproductive age, the investigators intend to conduct this single-center study focusing on patients consulting for non-medical fertility preservation.

Interventions

Usual follow-up

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
29 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

* Woman aged between 29 and 37 * Consultant for non-medical fertility preservation in the Reproductive Medicine Unit Port Royal, Cochin * Informed and not opposed to this research * Affiliated to a social security scheme

Exclusion criteria

* Pregnant women * Refusing to take part in the study * Under court protection, curatorship or guardianship * Women with a known malformation of the genital tract

Design outcomes

Primary

MeasureTime frameDescription
Transvaginal pelvic ultrasoundUp to month 6Search for endometriosis and adenomyosis on transvaginal pelvic ultrasound and characterisation of lesions.

Secondary

MeasureTime frameDescription
Self-questionnaireInclusionSocio-demographic data
Quality of life assessment (WHO-QOL-BREF)InclusionBetween 26 (Poor quality of life) and 130 (good quality of life)
Hospital Anxiety and Depression Scale (HADS)Inclusion2 scores between 0 (No anxiety or depression) and 21 (lots of anxiety and depression)

Countries

France

Contacts

CONTACTMathilde BOURDON, MD
mathilde.bourdon@aphp.fr00331 58 41 39 20
CONTACTMarie Benhammani-Godard
marie.godard@aphp.fr0033158411190

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026